Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ARCT 810

Next Previous
Drug Profile

ARCT 810

Alternative Names: ARCT-810; LUNAR-OTC

Latest Information Update: 09 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arcturus Therapeutics
  • Class RNA
  • Mechanism of Action Ornithine carbamoyltransferase expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ornithine carbamoyltransferase deficiency disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ornithine carbamoyltransferase deficiency disease

Most Recent Events

  • 06 Jan 2025 EMA approves the pediatric investigation plan for Ornithine transcarbamylase deficiency, prior to January 2025
  • 01 Nov 2024 Arcturus Therapeutics terminates a phase II trial in Ornithine carbamoyltransferase deficiency disease (In adolescents, In children, In adults) in Belgium, Sweden, Spain, France, Italy, United Kingdom (IV), due to slow enrollment (NCT05526066)
  • 10 Jun 2024 Phase-II clinical trials in Ornithine carbamoyltransferase deficiency disease (In adolescents, In children, In adults, In the elderly) in USA (IV) (NCT06488313)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top